bioRxiv / medRxivopen access
A randomized, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in adult idiopathic inflammatory myopathy
rheumatology
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 619208
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.